Wird geladen...
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been re...
Gespeichert in:
| Veröffentlicht in: | BMC Hematol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4498562/ https://ncbi.nlm.nih.gov/pubmed/26167286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12878-015-0029-1 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|